COMPOSITIONS COMPRISING CROSSLINKED CATION-BINDING POLYMERS AND CALCIUM AND/OR MAGNESIUM CATIONS, AND USES THEREOF
The present disclosure relates generally to crosslinked cation-binding polymers comprising monomers containing carboxylic acid groups, wherein the polymer contains calcium and/or magnesium cations that are counterions to about 15% to about 35% of the carboxylic acid groups in the polymer. The present disclosure also relates to methods of preparation of the polymers, and compositions, formulations, and dosage forms containing the polymers, and methods of using the polymers, compositions, formulations, and/or dosage forms to treat various diseases or disorders, including those involving ion and/or fluid imbalances.
1 . A crosslinked cation-binding polymer comprising:
a. monomers comprising carboxylate groups; and
b. calcium and/or magnesium cations,
wherein the calcium and/or magnesium cations are counterions to about 15% to about 35% of the carboxylate groups in said polymer, and
wherein the polymer comprises no more than about 5% sodium cations as counterions to the carboxylate groups in said polymer.
2 . The polymer of claim 1 , wherein said calcium and/or magnesium cations are counterions to about 20% to about 30% of the carboxylate groups in said polymer.
3 . The polymer of claim 1 , wherein said calcium and/or magnesium cations are counterions to about 21% of the carboxylate groups in said polymer.
4 . The polymer of claim 1 , wherein said calcium and/or magnesium cations are counterions to about 22% of the carboxylate groups in said polymer.
5 . The polymer of claim 1 , wherein said calcium and/or magnesium cations are counterions to about 25% of the carboxylate groups in said polymer.
6 . The polymer of claim 1 , wherein said calcium and/or magnesium cations are counterions to about 29% of the carboxylate groups in said polymer.
7 . The polymer of claim 1 , wherein said calcium and/or magnesium cations consist of calcium cations.
8 . The polymer of claim 1 , wherein counterions that are not calcium, magnesium, or sodium are hydrogen.
9 . The polymer of claim 1 , wherein the counterions to said carboxylate groups consist of said calcium and/or magnesium counterions, and hydrogen counterions.
10 . The polymer of claim 1 , wherein said monomer is acrylic acid, an acrylic acid derivative, or a salt thereof.
11 . The polymer of claim 10 , wherein said monomer is acrylic acid or a salt thereof.
12 . The polymer of claim 1 , wherein said polymer is crosslinked with a crosslinker selected from diethelyeneglycol diacrylate (diacryl glycerol), triallylamine, tetraallyloxyethane, allylmethacrylate, 1,1,1-trimethylolpropane triacrylate (TMPTA), and divinylbenzene.
13 . The polymer of claim 12 , wherein said crosslinked polymer is derived from acrylic acid monomers and TMPTA.
14 . The polymer of claim 1 , wherein said polymer has an in vitro saline absorption capacity of at least about 20 times its weight.
15 .- 16 . (canceled)
17 . A composition comprising:
a. the polymer of claim 1 ; and
b. a base,
wherein said base is present in an amount sufficient to provide up to about 0.8 equivalents of base per equivalent of carboxylic acid groups in said polymer.
18 .- 29 . (canceled)
30 . A composition comprising:
a. a crosslinked polyacrylate polymer comprising acrylic acid repeat units that comprise carboxylic acid groups, and calcium and/or magnesium cations, wherein said calcium cations are counterions to about 15% to about 35% of the carboxylate groups in said polymer, and wherein the polymer comprises no more than about 5% sodium cations as counterions to the carboxylate groups in said polymer; and
b. calcium carbonate,
wherein said calcium carbonate is present in an amount sufficient to provide up to about 0.8 equivalents of base per equivalent of carboxylic acid groups in said polymer.
31 .- 46 . (canceled)
47 . A dosage form comprising:
a. the polymer of claim 1 ; and
b. a base,
wherein said base is present in an amount sufficient to provide up to about 0.8 equivalents of base per equivalent of carboxylic acid groups in said polymer.
48 .- 171 . (canceled)
172 . A method of treating a disease or disorder in a subject in need thereof, said method comprising administering to said subject the polymer of claim 1 .
173 . A method of treating a disease or disorder in a subject in need thereof, said method comprising:
a. identifying a disease or a disorder in said subject, or identifying a risk that said subject will develop a disease or disorder; and
b. administering to said subject an effective amount of the polymer of claim 1 .
174 . The method of claim 172 , wherein said disease or disorder is one or more of: heart failure, a renal insufficiency disease, end stage renal disease, liver cirrhosis, chronic renal insufficiency, chronic kidney disease, fluid overload, fluid maldistribution, edema, pulmonary edema, peripheral edema, angioneurotic edema, lymphedema, nephrotic edema, idiopathic edema, ascites, cirrhotic ascites, chronic diarrhea, excessive interdialytic weight gain, high blood pressure, hyperkalemia, hypernatremia, abnormally high total body sodium, hypercalcemia, tumor lysis syndrome, head trauma, an adrenal disease, Addison's disease, salt-wasting congenital adrenal hyperplasia, hyporeninemic hypoaldosteronism, hypertension, salt-sensitive hypertension, refractory hypertension, hyperparathyroidism, renal tubular disease, rhabdomyolysis, electrical burns, thermal burns, crush injuries, renal failure, acute tubular necrosis, insulin insufficiency, hyperkalemic periodic paralysis, hemolysis, malignant hyperthermia, pulmonary edema secondary to cardiogenic pathophysiology, pulmonary edema with non-cardiogenic origin, drowning, acute glomerulonephritis, aspiration inhalation, neurogenic pulmonary edema, allergic pulmonary edema, high altitude sickness, Adult Respiratory Distress Syndrome, traumatic edema, cardiogenic edema, allergic edema, urticarial edema, acute hemorrhagic edema, papilledema, heatstroke edema, facial edema, eyelid edema, angioedema, cerebral edema, scleral edema, nephritis, nephrosis, nephrotic syndrome, glomerulonephritis, renal vein thrombosis, and/or premenstrual syndrome.
175 .- 177 . (canceled)